Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.458,76
-0,39%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immunocore Holdings PLC (IMCR) Immunocore Holdings PLC (IMCR) Notizie

IMCR

Immunocore (IMCR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMCR
DataOraFonteTitoloSimboloCompagnia
01/06/202414:00GlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
31/05/202422:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
31/05/202422:05GlobeNewswire Inc.Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
30/05/202422:00GlobeNewswire Inc.Immunocore to present at the Jefferies Global Healthcare ConferenceNASDAQ:IMCRImmunocore Holdings PLC
29/05/202413:00GlobeNewswire Inc.Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaNASDAQ:IMCRImmunocore Holdings PLC
28/05/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
08/05/202413:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMCRImmunocore Holdings PLC
08/05/202413:00GlobeNewswire Inc.Immunocore reports first quarter financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
24/04/202416:00GlobeNewswire Inc.Immunocore announces upcoming presentation and posters at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
04/04/202422:00GlobeNewswire Inc.Immunocore to present at upcoming investor conferencesNASDAQ:IMCRImmunocore Holdings PLC
05/03/202422:30GlobeNewswire Inc.Immunocore presented two posters at CROI 2024NASDAQ:IMCRImmunocore Holdings PLC
28/02/202413:34GlobeNewswire Inc.Immunocore reports fourth quarter and full year 2023 financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
28/02/202413:33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMCRImmunocore Holdings PLC
27/02/202400:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMCRImmunocore Holdings PLC
22/02/202413:00GlobeNewswire Inc.Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trialNASDAQ:IMCRImmunocore Holdings PLC
21/02/202413:00GlobeNewswire Inc.Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024NASDAQ:IMCRImmunocore Holdings PLC
31/01/202405:30GlobeNewswire Inc.Immunocore Prices Upsized Convertible Senior Notes OfferingNASDAQ:IMCRImmunocore Holdings PLC
29/01/202422:05GlobeNewswire Inc.Immunocore Announces Proposed Convertible Senior Notes OfferingNASDAQ:IMCRImmunocore Holdings PLC
05/01/202413:00GlobeNewswire Inc.Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentationNASDAQ:IMCRImmunocore Holdings PLC
03/01/202413:00GlobeNewswire Inc.Immunocore to present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IMCRImmunocore Holdings PLC
02/01/202422:57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
30/11/202310:00GlobeNewswire Inc.Levicept Appoints Eliot Forster as CEONASDAQ:IMCRImmunocore Holdings PLC
07/11/202313:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMCRImmunocore Holdings PLC
07/11/202313:00GlobeNewswire Inc.Immunocore Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IMCRImmunocore Holdings PLC
01/11/202321:01GlobeNewswire Inc.Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023NASDAQ:IMCRImmunocore Holdings PLC
21/10/202314:45GlobeNewswire Inc.Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trialNASDAQ:IMCRImmunocore Holdings PLC
06/10/202313:01GlobeNewswire Inc.Immunocore announces upcoming presentation and posters at ESMO 2023NASDAQ:IMCRImmunocore Holdings PLC
10/08/202313:00GlobeNewswire Inc.Immunocore Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IMCRImmunocore Holdings PLC
03/08/202314:00GlobeNewswire Inc.Immunocore to report second quarter 2023 financial results and host call on August 10, 2023NASDAQ:IMCRImmunocore Holdings PLC
15/06/202323:18Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:IMCRImmunocore Holdings PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMCR

La tua Cronologia

COIN
TDXETH
EU
U199S
U199S
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network